44.81
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EXEL Giù?
Forum
Previsione
Exelixis Inc Borsa (EXEL) Ultime notizie
Exelixis Insiders Sell US$12m Of Stock, Possibly Signalling Caution - simplywall.st
Long Term Trading Analysis for (EXEL) - news.stocktradersdaily.com
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Truist Securities raises Exelixis stock price target to $56 on positive outlook - Investing.com Canada
Truist Lifts Price Target on Exelixis to $56 From $55, Keeps Buy Rating - MarketScreener
Exelixis to Release Second Quarter 2025 Financial Results on Monday, July 28, 2025 - BioSpace
Press Release: Exelixis to Release Second Quarter 2025 Financial Results on Monday, July 28, 2025 - 富途牛牛
Exelixis (EXEL) is an Incredible Growth Stock: 3 Reasons Why - sharewise.com
Analysts Offer Insights on Healthcare Companies: Medtronic (MDT) and Exelixis (EXEL) - The Globe and Mail
Barclays Remains a Hold on Exelixis (EXEL) - The Globe and Mail
Assessing Exelixis: Insights From 12 Financial Analysts - Nasdaq
RBC Capital Keeps Their Buy Rating on Exelixis (EXEL) - The Globe and Mail
Exelixis cut to sector perform at RBC as cash flows fairly valued - Seeking Alpha
RBC Downgrades Exelixis to Sector Perform From Outperform, Lifts Price Target to $50 From $45 - MarketScreener
Exelixis (EXEL): Why Now is the Time to Act on Strong Clinical and Financial Catalysts - AInvest
Exelixis: I Was Wrong To Be Too Cautious (Rating Upgrade) - Seeking Alpha
Exelixis Surges 35.2% in Three Months: Buy or Sell the Stock? - The Globe and Mail
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term - Yahoo Finance
Exelixis’s SWOT analysis: stock poised for growth amid pipeline progress - Investing.com
Zacks Industry Outlook Highlights Exelixis, Verona Pharma, Alkermes, Kiniska Pharmaceuticals and Immunocore - Yahoo Finance
Cancer index outperforms broader markets with 13% Q2 rebound - BioWorld MedTech
Exelixis, Inc. (EXEL) Stock Analysis: Riding the Wave of 30.60% Revenue Growth in the Biotechnology Sphere - DirectorsTalk Interviews
Zacks.com featured highlights include Exelixis, Lyft and Kinross Gold - Yahoo Finance
Stephens Upgrades Exelixis (EXEL) Stock, Raises PT - Insider Monkey
Exelixis (EXEL) Surges 7.4%: Is This an Indication of Further Gains? - MSN
The Zacks Analyst Blog Highlights Sprouts Farmers Market, Royal Gold, Thomson Reuters, Woodward and Exelixis - The Globe and Mail
Stifel Nicolaus Sticks to Its Hold Rating for Exelixis (EXEL) - The Globe and Mail
Truist Raises Price Target on Exelixis to $55 From $43, Keeps Buy Rating - MarketScreener
Exelixis' Zanzalintinib: A Breakthrough in Colorectal Cancer and a Catalyst for Growth - AInvest
Exelixis (EXEL) Awaits EU Decision on CABOMETYX Approval | EXEL Stock News - GuruFocus
Those who invested in Exelixis (NASDAQ:EXEL) three years ago are up 102% - Yahoo Finance
Here's Why Exelixis (EXEL) is a Strong Value Stock - Yahoo Finance
How to Take Advantage of moves in (EXEL) - news.stocktradersdaily.com
Exelixis’s SWOT analysis: cabozantinib’s strength, zanzalintinib’s potential drive stock outlook - Investing.com Canada
Zacks.com featured highlights include Flex, CVS Health, Urban Outfitters and Exelixis - Yahoo Finance
EXEL: HC Wainwright & Co. Raises Price Target to $47.00 | EXEL S - GuruFocus
Exelixis stock maintains buy rating at H.C. Wainwright on promising data - Investing.com Canada
Why Is Exelixis (EXEL) Down 7.2% Since Last Earnings Report? - Yahoo Finance
Exelixis, Inc.'s (NASDAQ:EXEL) Stock's On An Uptrend: Are Strong Financials Guiding The Market? - simplywall.st
EXEL: HC Wainwright & Co. Raises Price Target to $47.00 | EXEL Stock News - GuruFocus
Exelixis (EXEL) Stock Target Boosted by H.C. Wainwright | EXEL S - GuruFocus
Promising Clinical Data and Favorable Safety Profile Drive Buy Rating for Exelixis - TipRanks
Exelixis (EXEL) Stock Target Boosted by H.C. Wainwright | EXEL Stock News - GuruFocus
Indexes Rise But Growth Plays Hit; Quanta Services, Exelixis, Google In Focus - Investor's Business Daily
Kalkine: Exelixis Joins Momentum Wave Ahead of Russell 1000 Rebalance - Kalkine Media
BofA Hikes Exelixis, Inc. (EXEL) Target Amid CRC Caution - MSN
3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL) - Yahoo Finance
Exelixis, Inc. (EXEL) Stock Analysis: A Biotech Powerhouse with Robust Revenue Growth - DirectorsTalk Interviews
Exelixis, Inc. (NASDAQ:EXEL) Stock Holdings Increased by GAMMA Investing LLC - Defense World
Bank of America Forecasts Strong Price Appreciation for Exelixis (NASDAQ:EXEL) Stock - Defense World
Brokerages Set Exelixis, Inc. (NASDAQ:EXEL) Price Target at $38.94 - Defense World
Zacks Research Has Bullish Forecast for Exelixis Q2 Earnings - Defense World
Exelixis Escapes Cancer Drug Invalidity Bid At PTAB - Law360
Are You Looking for a Top Momentum Pick? Why Exelixis (EXEL) is a Great Choice - Yahoo Finance
Analyst Expectations For Exelixis's Future - Benzinga
Exelixis (EXEL) Sees Price Target Raised by B of A Securities | - GuruFocus
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):